Leukemia Research
Volume 24, Issue 12 , Pages 983-992 , December 2000

Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients

Received 6 March 2000 ,Accepted 23 June 2000.

References 

  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 1982;51:189
  2. Kerkhofs H, Hermanns J, Haak HL, Leeksma HW. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br. J. Haematol. 1987;65:73
  3. Ribera JM, Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria. Br. J. Haematol. 1987;65:307
  4. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br. J. Haematol. 1985;59:425
  5. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74:395
  6. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes (MDS): analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6:52
  7. Aul C, Gattermann N, Germing U, Runde V, Heyll A, Schneider W. Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score. Leukemia. 1994;8:1906
  8. Goasguen JE, Garand R, Bizet M, Bremond JL, Gardais J, Callat MP, et al. Prognostic factors of myelodysplastic syndromes — a simplified 3-D scoring system. Leuk. Res. 1990;14:255
  9. Oguma S, Yoshida Y, Uduino H, Mackawa T, Nomura T, Mizogudi H. Clinical characteristics of japanese patients with primary myelodysplastic syndromes: a cooperative study based on 838 cases. Leuk. Res. 1995;19:219
  10. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, et al. Cytogenetic analysis has a strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia. 1993;7:1315
  11. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079
  12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French–American–British Cooperative Leukaemia Group. Br. J. Haematol. 1994;87:746
  13. Michaux JL, Martiat P. Chronic myelomonocytic leukaemia (CMML). A myelodysplastic or myeloproliferative syndrome?. Leuk. Lymphoma. 1993;9:35
  14. Groupe Francais de Cytogenetique Hematologique . Chronic myelomonocytic leukaemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Cancer Genet. Cytogenet. 1991;55:57
  15. Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML-dysplastic versus proliferative type. Leuk. Res. 1998;22:871
  16. Seymour JF, Estey EH. The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes. Leuk. Lymphoma. 1995;17:79
  17. Germing U, Strupp C, Giagounidis AS, Meckenstock G, Aul C. RAEB-T: a heterogenous entity?. Leuk. Res. 1999;23(Suppl. 1):A169
  18. Gattermann N, Aul C, Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br. J. Haematol. 1990;74:45
  19. Garand R, Gardais J, Bizet M. Heterogeneity of acquired idiopathic sideroblastic anemia (AISA). Leuk. Res. 1992;16:463
  20. Germing U, Gattermann N, Hildebrandt B, Aivado M, Aul C. Two types of acquired idiopathic sideroblastic anaemia: a time-tested distinction. Br J Haematol 2000;108:724.
  21. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br. J. Haematol. 1995;91:612
  22. Michels S, Chan W, Jakubowski D, Vogler R. Unclassifiable myelodysplastic syndrome: a study of sixteen cases with a proposal for a new subtype. Lab. Invest. 1990;62:67;abstract
  23. Rosati S, Mick R, Xu F, Stonys E, LeBeau MM, Larson R, et al. Refractory cytopenia with multilineage dysplasia: further characterization of an ‘unclassifiable’ myelodysplastic syndrome. Leukemia. 1996;10:20
  24. Matsuda A, Jinnai I, Yagasaki F, Kusumoto S, Minamahisamatu M, Honda S, et al. Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia. 1998;12:482
  25. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting — Airlie House, Virginia, November 1997. J. Clin. Oncol. 1999;17:3835
  26. Bennett J. The World Health Organization (WHO) classification of acute leukemias and the myelodysplastic syndromes. Int J Hematol, in press.
  27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958;53:457
  28. Cox DR. Regression models and life-tables. J. R. Stat. Soc. 1972;34:187
  29. Verwilghen RL, Boogaerts MA. The myelodysplastic syndromes. Blood Rev. 1987;1:34
  30. Cervera J, Sanz GF, Vallespie T, delCanizo MC, Irriguible D, Lopez F, et al. Does WBC really define two different subtypes of chronic myelomonocytic leukemia (CMML)? Analysis of a series of 119 patients. Leuk. Res. 1997;21(Suppl. 1):A27
  31. Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H, et al. Clinical implication of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia. 1993;7:499
  32. Kuriyama K, Miyazaki Y, Arimura K, Nagai K, Nakamura H, Matsuo T, et al. Morphological comparison of dysplastic changes between ne novo acute leukemia (AML) with trilineage myelodysplasia and AML developed from de novo myelodysplastic syndromes. Leuk. Res. 1995;19:121
  33. Matsuda A, Jinnai I, Yagasaki F, Kusumoto S, Murohashi I, Bessho M, et al. New system for assessing the prognosis of refractory anemia patients. Leukemia. 1999;13:1727
  34. Kuriyama K, Tomonaga M, Matsuda T, Ginnai I, Ichimaru M. Diagnostic significance of detecting pseudo-Pelger–Huet anomalies and micromegakaryocytes in myelodysplastic syndromes. Br. J. Haematol. 1986;63:665

PII: S0145-2126(00)00088-6

doi: 10.1016/S0145-2126(00)00088-6

Leukemia Research
Volume 24, Issue 12 , Pages 983-992 , December 2000

Article Tools

* Image Usage & Resolution